scispace - formally typeset
K

K. J. Schjoedt

Researcher at Steno Diabetes Center

Publications -  17
Citations -  1607

K. J. Schjoedt is an academic researcher from Steno Diabetes Center. The author has contributed to research in topics: Diabetic nephropathy & Renal function. The author has an hindex of 13, co-authored 17 publications receiving 1519 citations. Previous affiliations of K. J. Schjoedt include Erasmus University Rotterdam & Health Science University.

Papers
More filters
Journal ArticleDOI

Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study

Kasper Rossing, +4 more
- 01 Sep 2005 - 
TL;DR: It is suggested that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.
Journal ArticleDOI

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

Kasper Rossing, +4 more
- 01 Sep 2005 - 
TL;DR: Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg.
Journal ArticleDOI

Beneficial impact of spironolactone in diabetic nephropathy.

K. J. Schjoedt, +20 more
- 01 Dec 2005 - 
TL;DR: It is suggested that spironolactone treatment on top of recommended antihypertensive treatment reduces blood pressure and may offer additional renoprotection in type 1 diabetic patients with diabetic nephropathy.
Journal ArticleDOI

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

K. J. Schjoedt, +5 more
- 17 Nov 2004 - 
TL;DR: The data suggest that aldosterone escape during long-term blockade of the renin–angiotensin–aldosterone system is associated with an enhanced decline in GFR in patients with type 1 diabetes and diabetic nephropathy.
Journal ArticleDOI

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

K. J. Schjoedt, +7 more
- 01 Aug 2006 - 
TL;DR: It is suggested that spironolactone treatment on top of recommended renoprotective treatment including maximal renin-angiotensin system blockade may offer additional renoprotsection in patients with diabetic nephropathy and nephrotic range albuminuria.